Research Article
Formulation, Optimization, and Characterization of Repaglinide Loaded Nanocrystal for Diabetes Therapy
Table 4
Measurement of % entrapment efficiency, PDI, particle size, In vitro drug release, and zeta potential.
| Sr. number | Dependent variable | Batch | PDI | In vitro drug release study (%) | Particle size (nm) | Zeta potential (mv) | (Mean ± SD), = 3 | (Mean ± SD), = 3 |
(Mean ± SD), = 3 | (Mean ± SD), = 3 |
| 1 | NC 1 | 0.510 ± 0.12 | 55.38 ± 1.25 | 386.7 ± 10.88 | −22.9 ± 0.48 | 2 | NC 2 | 0.267 ± 0.06 | 69.08 ± 0.64 | 213.5 ± 8.68 | −23.4 ± 1.22 | 3 | NC3 | 0.248 ± 0.04 | 80.58 ± 1.71 | 187 ± 5.09 | −29.4 ± 1.00 | 4 | NC 4 | 0.665 ± 0.08 | 59.64 ± 1.1 | 743.5 ± 12.16 | −16.4 ± 2.43 | 5 | NC 5 | 0.6 ± 0.1 | 65.33 ± 1.41 | 543.4 ± 9.66 | −25.8 ± 0.52 | 6 | NC 6 | 0.570 ± 0.05 | 78.26 ± 2.08 | 443.7 ± 7.56 | −28 ± 2.56 | 7 | NC 7 | 0.478 ± 0.07 | 32.88 ± 0.98 | 619 ± 10.74 | −5.69 ± 0.89 | 8 | NC 8 | 0.355 ± 0.05 | 44.69 ± 1.21 | 509.4 ± 11.56 | −7.67 ± 0.78 | 9 | NC 9 | 0.540 ± 0.14 | 52.71 ± 1.29 | 751 ± 14.13 | −1.19 ± 1.55 |
|
|